Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, January 10, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE:JNJ), Epizyme Inc. (NASDAQ:EPZM), Health Management Associates Inc. (NYSE:HMA), DENTSPLY International Inc. (NASDAQ:XRAY) and Charles River Laboratories (NYSE:CRL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Johnson & Johnson Research Report
On January 7, 2014, Johnson & Johnson's subsidiary, Janssen Research & Development LLC (Janssen) announced the early stopping of PCYC-112-CA, the Phase 3 study of IMBRUVICA (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed significant difference in progression-free survival (PFS) as compared to the control, the primary endpoint of the study. "We're delighted with this outcome, and look forward to sharing these results with the scientific community and Health Authorities," said Peter F. Lebowitz, MD, PhD, Oncology Therapeutic Area Head at Janssen, "This Phase 3 randomized study provides a useful head-to-head comparison of single agent ibrutinib versus ofatumumab, and builds upon the early evidence of clinical benefit observed in the ibrutinib Phase 2 program." According to Janssen, the IDMC unanimously recommended stopping the study early based on a planned interim analysis, in which statistically significant differences in PFS (as assessed by an independent review committee) and OS were observed. According to the Company, the IDMC agreed that these results suggest evidence of clinical benefit as well as tolerable safety profile in patients receiving ibrutinib as compared to intravenous doses of ofatumumab. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Epizyme Inc. Research Report
On January 6, 2014, Epizyme Inc. (Epizyme) announced the achievement of the proof of concept (POC) milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the Company's collaboration with Celgene Corporation (Celgene). Epizyme informed that the milestone was achieved by objective responses in patients with translocations of the MLL gene (MLL-r). Epizyme said that the patients are currently enrolled in the fourth dose cohort in the dose escalation stage of the ongoing Phase 1 clinical study and are receiving uninterrupted treatment with EPZ-5676. Epizyme added that a development candidate milestone has been achieved for one of the three histone methyltransferase (HMT) targets included in the Company's collaboration with GlaxoSmithKline (GSK), earning a $4 million payment. Robert Gould, Ph.D., CEO at Epizyme, said, "We have achieved the proof of concept milestone for EPZ-5676, our first-in-class DOT1L inhibitor, in our Celgene collaboration, initiated an ongoing Phase 1 study of EPZ-6438, our first-in-class EZH2 inhibitor, in our Eisai collaboration, achieved a Development Candidate milestone in our GSK collaboration, and continue to advance our pipeline of personalized therapeutics for patients with genetically defined cancers." The Full Research Report on Epizyme Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Health Management Associates Inc. Research Report
On January 7, 2014, Health Management Associates Inc.'s (Health Management) stock rose 1.43%, ending the day's trading at $13.51. Over the previous three trading sessions, shares of Health Management gained 1.58%, compared to the S&P 500 Index, which gained 0.32% during the same period. The Full Research Report on Health Management Associates Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
DENTSPLY International Inc. Research Report
On January 7, 2014, DENTSPLY International Inc.'s (DENTSPLY) stock increased 1.54%, ending the day's trading session at $48.64. Over the previous three trading sessions, shares of DENTSPLY gained 1.42% compared to the Nasdaq Composite Index, which gained 0.24% during the same period. The Full Research Report on DENTSPLY International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Charles River Laboratories Research Report
On January 7, 2014, Charles River Laboratories' (Charles River) stock gained 6.27%, ending the day at $56.30. Over the previous three trading sessions, shares of Charles River gained 6.47%, compared to the S&P 500 Index, which gained 0.32% during the same period. The Full Research Report on Charles River Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner